# Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

> **NCT05413356** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Bronchiolitis Obliterans Syndrome
- Hematologic Malignancy

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05413356
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05413356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05413356, "Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05413356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*